Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03384940 · ClinicalTrials.gov registry record · Phase 2
DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)
A Phase 2 study, sponsored by Daiichi Sankyo Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 86
- Enrollment target
NCT03384940 is a Phase 2 study that has completed, run by Daiichi Sankyo Co.. The registered enrollment target is 86 participants.
The verdict
NCT03384940, a Phase 2 study, has completed, sponsored by Daiichi Sankyo Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 86 participants
- Enrollment target
Study Summary
The main objective of this study is to test the safety and effectiveness of DS-8201a for participants with HER2-expressing advanced colorectal cancer.
Interventions
- DRUG DS-8201a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2018-02-23 |
| Est. Completion | 2020-11-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03384940
The ClinicalTrials.gov registry entry for NCT03384940 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo Co., which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DS-8201a is the first listed.
NCT03384940 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03384940 about?
NCT03384940 is a clinical study titled "DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)". The main objective of this study is to test the safety and effectiveness of DS-8201a for participants with HER2-expressing advanced colorectal cancer.
What is the current status of trial NCT03384940?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 86 participants. The study started on 2018-02-23. Estimated completion is 2020-11-10.
What interventions are being tested in trial NCT03384940?
The interventions under investigation include: DS-8201a (DRUG).
Who is sponsoring clinical trial NCT03384940?
This trial is sponsored by Daiichi Sankyo Co., which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.